Navigation Links
Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
Date:8/31/2007

Gov. Kaine's independent panel urges less restrictive commitment standard

ARLINGTON, Va., Aug. 31 /PRNewswire-USNewswire/ -- What happened to keep Seung Hui Cho from getting needed treatment and at what point could the Virginia Tech massacre have been prevented? The state-appointed panel charged with answering those questions released its report today, stating in part that "The Virginia standard for involuntary commitment is one of the most restrictive in the nation and is not uniformly applied."

The report details the many lost opportunities to help Cho and makes recommendations to improve Virginia's restrictive mental health treatment law.

The panel recommended that the involuntary treatment criteria be improved to "allow involuntary treatment in a broader range of cases involving severe mental illness." The current standard for involuntary commitment in Virginia for someone with a severe mental illness requires a person to be an "imminent danger to self or others" before he or she can be court-ordered to treatment. This makes it difficult, if not impossible, to treat someone before they have harmed his or her self or someone else, or threatened to do so. About half of states have more humane standards that focus on the person's deteriorating condition and "need for treatment," rather than requiring them to deteriorate to "dangerousness."

The panel recommended that "reports of prior psychiatric history" be presented at the commitment hearing. Current Virginia law instructs magistrates to rely solely on what is happening currently with a person with untreated severe mental illness, ignoring what happened in the past. That means past episodes of violence, psychiatric history, and past treatment are not considered. As is clear from the extensive report on Cho, past history is not only relevant, but oftentimes critical.

"Gov. Kaine and the independent panel should be commended for not only identifying many of the flaws in the
'/>"/>

SOURCE Treatment Advocacy Center
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Once a Lawn Mower, a Self-made Billionaire Makes a Lasting Gift to Virginia Tech
2. West Virginia Organizes a Program to Fight Obesity
3. Indians Add to Rich Diversity of Virginia Tech
4. Virginia Tech. Shooter -Human Rights or Innocent Lives
5. Virginia Tech Shooters Mental Health Records No More Secret
6. Fire Ants are Emerging Nuisance for Virginians
7. Australian Devises Online Game Based on Virginia Tech Shootout
8. Pain Doctor in Virginia Sentenced to Five Years Imprisonment
9. Five Killed by Methane Gas on Virginia Farm
10. FDA may speed review of new drugs
11. Scientists review SARS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2008)... Fans Can ,Start Their Engines, and Nominate Now a...TSBURGH, July 9 /PRNewswire/ -- TUMS, one of the m...elief, is launching a nationwide search for,one lu...QuikPak 500 Sprint,Cup Series race at Martinsville...., (Photo: http://www.newscom.com/cgi-bin/prnh/2...
(Date:7/9/2008)...o be heavier if they spend a lot of time on the In...uly 9 (HealthDay News) -- Teen girls who spend a ... their weight creeping slowly up than adolescents ...n, new research shows. , And the association be...the researchers accounted for the amount of exerci...
(Date:7/9/2008)... global needs for the increasingly complex healthc... YORK, July 9 /PRNewswire/ -- Cohn & Wolfe has ann...ealthcare public relations firm,specializing in a... which,will be led by Jill Dosik as president, off... marketing strategy and leading-edge digital healt...
(Date:7/9/2008)...and, July 9 /Xinhua-PRNewswire/ -- Chindex,Interna...ican provider of,international healthcare services...epublic of China, today announced that its Healthc...ncommercial China travel health,information websit...p://www.ChinaHealthWatch.org ) is a,comprehensive...
Breaking Medicine News(10 mins):Health News:TUMS Announces Nationwide Search for Grand Marshal at TUMS QuikPak 500 2Health News:Surfing to a Higher Weight 2Health News:Surfing to a Higher Weight 3Health News:Cohn & Wolfe Launches GCI Health, One of the World's Largest Healthcare Public Relations Firms 2Health News:Chindex's United Family Healthcare Launches ChinaHealthWatch.org - A global resource for travelers to China 2
Detect masses in the breast
... injury to most or all of both lungs. Patients wit...re on life support. //A new study finds the age of...fter a trauma. ARDS is not a specific disease; ins... associated with a number of diseases including pn...
...of viral particles isolated from humans with SARS ...ed //and being held in a retail food market. The a...99.8 percent genetically identical to a virus that...y syndrome, or SARS, in humans. Their findings sug...
...rmone could suppress the appetites of lean people.... obese people because studies of another appetite-...nting. "We had to do a second trial to see if obes...ne, said researchers. The answer: "Yes, they are. ...
Other Medicine News:Health News:SARS research confirms link to animals 2Health News:Extra hormone found to cut appetite by a third 2
(Date:7/9/2008)...n of Primary Tumors From Metastases in the ...fying Whether a Brain Malignancy is a Primary Tumo...thologists Using Current Technologies, Accurately ...Critical for Optimal Tre...ey, July 9,/- Rosetta Genom...
(Date:7/8/2008)...Newswire/ -- After meeting on July 1st and,2nd an ...es drugs should,undergo trials to rule out cardiov...S endocrinologists agree with this recommendation,...vascular and metabolic primary market,research and...l Life,Sciences Industry., On July 3rd AlphaDetai...
(Date:7/8/2008)...r symptom control versus Concerta from 30 minute...endpoints,- Only Focalin XR provided onset of effe...analysis suggests Focalin XR provides comparable e...2 hours - Symptoms of Attention Deficit/Hyperact...hild,s ability to focus and learn in an educationa...
(Date:7/7/2008)...FirstCall/ -- Pulmo BioTech Inc. (OTC,Bulletin Boa...lmoScience,Inc. has completed the bio-distribution...ulmoBind technology of Molecular Imaging of the va...es a molecule designed to bond specifically to,cer...the chosen molecule,was designed to bond only to t...
Breaking Medicine Technology:Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain 2Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain 3Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain 4AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel's Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications. 2Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 2Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 3Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 4Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 5Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 6Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 7Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 8Pulmo BioTech Inc. Completes Bio-Distribution Studies 2Pulmo BioTech Inc. Completes Bio-Distribution Studies 3New Treatment Shows Promise for Excessive Drinking 21424 1New Treatment Shows Promise for Excessive Drinking 21424 2Syneron Signs Multi Year Exclusive Equipment Provider Agreement with Sono Bello Contouring Centers to Offer LipoLite 28TM 29 and VelaShape 28TM 29 21422 1Syneron Signs Multi Year Exclusive Equipment Provider Agreement with Sono Bello Contouring Centers to Offer LipoLite 28TM 29 and VelaShape 28TM 29 21422 2Syneron Signs Multi Year Exclusive Equipment Provider Agreement with Sono Bello Contouring Centers to Offer LipoLite 28TM 29 and VelaShape 28TM 29 21422 3The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to 2416 7 Billion By 2016 21420 1The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to 2416 7 Billion By 2016 21420 2Linkwell Corporation Disinfection Epidemic Prevention Teams Enter into Sichuan Earthquake Area 21418 1Linkwell Corporation Disinfection Epidemic Prevention Teams Enter into Sichuan Earthquake Area 21418 2Linkwell Corporation Disinfection Epidemic Prevention Teams Enter into Sichuan Earthquake Area 21418 3
... Switzerland, April 3, 2007 (PRIME NEWSWIRE) -- Ne...ogical and,pharmacokinetic profiles of Basilea,s (...ole and isavuconazole. Studies reported,both for c...phalosporin in late-stage development, and for isa...asive fungal infections,yielded further data on t...
...France, April 04, 2007 /PRNewswire/ -- Novagali Ph...y specialized in,ophthalmology, announces today po...f Vekacia(R) in children suffering from Vernal,Ker...t was shown,that both symptoms and signs of diseas...ermore, the tolerability to Vekacia(R),was excelle...
Other Medicine Technology:Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 2Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 4Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 5Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 6Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 7Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2
Rapid reagent impregnated disk test for presumptive identification of Candida albicans.
...sive Electronic Medical Records for small and larg...tient flow from check-in to check-out. Review the ...rent medications, to allergies, labs and charts al...ecords immediately. Communicate electronically wit...
Written specifically for urologists by a urologist, this EMR software utilizes touch screen technology to streamline your workflow and virtually eliminate the use of a cumbersome mouse. Its intuitive
...t Record is a new generation of advanced Electroni...the largest, numerically codified medical vocabula... data elements embedded in MedcomSoft Record, heal... an easy and intuitive point and click system and ...
Medicine Products: